Our Team
Office
Tel
Education
Admissions & Qualifications
Founder and
Managing Partner
Edwin Kwok
Our founder and managing parter, Edwin Kwok, is a leading Corporate and Capital Markets lawyer with extensive experience advising major investment banks, healthcare and TMT issuers, life science and biotech firms, Chinese state-owned enterprises, real estate and property management companies on their initial public offerings, cross-border acquisitions, public takeovers, privatizations, spin-offs, corporate compliance, SFC’s licensing and follow-on offerings of equity and debt securities.
Edwin has extensive experience includes advising on some of the most significant capital markets and mergers and acquisitions transactions in the Asia region. He has advised on numerous securities offerings on the Hong Kong Stock Exchange, public takeovers and listing rules regulated notifiable transactions, some of which were highly complex involving complicated cross border implications. He has represented a number of biotech and healthcare companies in their listings on the Main Board of the Hong Kong Stock Exchange, including RemeGen, Akeso, Brii Biosciences, Pharmaron Beijing, Peijia Medical, Honliv Healthcare Management, Cryofocus Medtech, Jenscare Scientific, Acotec Scientific, Shanghai Bio-heart, Shanghai HeartCare Medical, KeyMed Biosciences, Jacobio Pharmaceuticals, Hygeia Health, and Simcere Pharmaceutical. He is also deeply experienced with privatizations and takeovers of Hong Kong listed companies.
Before founding our firm, Edwin has been a partner at O’Melveny & Myers and Paul Hastings. He has led in building and positioning O’Melveny & Myers as the market leader for life science and biotech capital markets transactions following the adoption by the Hong Kong Stock Exchange of Chapter 18A into its listing rules. Edwin led the O’Melveny team for RemeGen’s debut on the Hong Kong Stock Exchange in 2020, which was the world’s largest biopharma primary listing and IPO of 2020 and recognized as deal of the year for 2020 by China Business Law Journal. Edwin was named to the A-List of China’s 100 Elite Foreign Lawyers by China Business Law Journal in 2022, and to the “The A-List 2023-2024: Growth Drivers” by China Business Law Journal in 2024. Edwin has also served as in-house legal counsel and capital markets consultant for N.M. Rothschild & Sons (Hong Kong) Limited and China Unicom Limited.
Edwin has been highly praised by various legal league tables and publications such as Chambers Global, Chambers Greater China Region, Legal500 and IFLR1000.
Selected accolades include:
- Ranked in the latest Chambers Greater China Region 2025 (International Firms (Equity));
- “Edwin is very responsive and is always able to give us practical solutions.” (Chambers Greater China Region 2024)
- “Edwin has always been a technically strong lawyer who follows up on matters closely. He’s not just technically strong but also a practical lawyer. He’s a very smooth operator in dealing with clients.” (Chambers Greater China Region 2024)
- “Edwin really knows Hong Kong capital markets, is highly responsive and is both capable and clever. He has a razor-sharp mind and is very thorough. He’s an excellent strategic thinker, a pragmatic lawyer and is very commercially savvy.” (Chambers Greater China Region 2023)
- “Edwin is a very experienced lawyer who solves sophisticated issues for his clients and gets things done.” (Chambers Greater China Region 2023)
- “Edwin’s quite resourceful and is quite experienced in our line of work, which is Hong Kong listings. He’s always there when we need advice and is quite proactive in giving his view as well.” (Chambers Greater China Region 2023)
- “Edwin has the ability to look through the big picture of the entire transaction and applies excellent judgementto it. He is always reassuring and inspires confidence in his clients; I can see that the bankers really trust him.” (Chambers Greater China Region 2022)
- “Edwin stays very calm, no matter how strong the time pressure is, and our team also noted that Edwin has an encyclopedic knowledge of Hong Kong IPOs and can easily point us to any precedent that can shed light on the issues we face.” (Chambers Greater China Region 2022)
- “As a brokerage lawyer, Edwin Kwok can give the sponsor clear feedback on key issues. As an issuer’s lawyer, he can also fully protect the interests of the issuer and have an effective relationship with the sponsor.” (Legal 500 2022)
- “Edwin Kwok is very impressive in terms of managing clients and legal matters” (Legal 500 2021)
- “Edwin’s equity capital markets and M&A experience makes him particularly well placed to assist businesses with raising capital and undertaking strategically important investment activities” (Legal 500 2018)
EXPERIENCE
HK IPO Transactions
- CLSA Limited, Guotai Junan Securities (Hong Kong) Limited, CMB International Capital Limited, China Galaxy International Securities (Hong Kong) Co., Limited and Kingkey Securities Group Limited in the HK$2.088 billion block trade of shares in XtalPi Holdings Limited
- CLSA Limited, Guotai Junan Securities (Hong Kong) Limited and Kingkey Securities Group Limited in the HK$1.13 billion block trade of shares in XtalPi Holdings Limited
- RemeGen Co., Ltd. in its US$515 million IPO and listing on the Hong Kong Stock Exchange (Deal of the year for 2020 by China Business Law Journal and Megatrend Deal of the Year (Healthcare) by FinanceAsia)
- OrbusNeich Medical Group in its US$62 Million IPO on the Main Board of the Stock Exchange
- Haitong International Capital Limited and CCB International Capital Limited and other underwriters in the IPO of Huafang Group Inc.
- Asia Ventures III and ERVC Healthcare (both of whose general partner is Eight Roads GP) and F-Prime Capital (an affiliate of Fidelity Investments) in the IPO for Sipai Health Technology Co., Ltd.
- ABCI Captial Limited, CICC Hong Kong Securities Limited and other underwriters in the IPO of Lushang Life Services Co., Ltd on the Stock Exchange
- BNP Paribas, China Construction Bank International, Industrial and Commercial Bank of China International and other underwriters in the spin-off and approximately US$126 million listing of Central China Management on the Hong Kong Stock Exchange
- CCB International Capital Limited as sole sponsor and other underwriters in the US$85 million IPO and listing of Kangqiao Service Group on the Hong Kong Stock Exchange
- J.P. Morgan, BofA Securities, CICC and Haitong International as joint sponsors and other underwriters in the approximately US$1.67 billion secondary listing of GDS Holdings Limited on the Hong Kong Stock Exchange
- Pharmaron in its approximately US$588 million H share offering in Hong Kong
- Tian Tu Capital Co., Ltd. in its approximately HK$1.13 billion IPO and listing of H shares on the Main Board of the Stock Exchange
- Brii Biosciences Limited in its US$318 million IPO and listing on the Hong Kong Stock Exchange
- China International Capital Corporation Hong Kong Securities Limited and 18 other underwriters in the HK$1.18 billion IPO of Beijing Fourth Paradigm Technology Co., Ltd. on the Main Board of the Stock Exchange
- 3D Medicines Inc in its US$52 million IPO and listing on the Hong Kong Stock Exchange
- Cryofocus Medtech (Shanghai) Co., Ltd in its IPO and listing on the Hong Kong Stock Exchange
- Rainmed Medical in its IPO and listing on the Stock Exchange
- Keymed Biosciences in its US$398 million IPO and listing on the Hong Kong Stock Exchange
- Acotec Scientific in its US$210 million IPO and listing on the Hong Kong Stock Exchange
- Hua Medicine in its US$110 million Chapter 18A biotech company IPO sponsored by Goldman Sachs and CLSA Limited
- Peijia Medical Group in its US$302 million IPO and listing on the Hong Kong Stock Exchange
- Shanghai Bioheart in its HK$441 million IPO and listing on the Hong Kong Stock Exchange
- Jacobio in its US$174 million IPO and listing on the Hong Kong Stock Exchange
- Fidelity and Eight Roads, as major shareholder of Innovent Biologics, in Innovent Biologics’ US$412 million IPO on the Main Board of the Hong Kong Stock Exchange
- Jenscare Scientific Co., Ltd. in its IPO and listing on the Stock Exchange
- RemeGen Co., Ltd in its current A share listing of approximately US$410 million (RMB 2.61 billion) the Sci-Tech Innovation Board of the Shanghai Stock Exchange
- Goldman Sachs in the IPO and listing of Tencent Holdings Limited on the Hong Kong Stock Exchange
- Yonghe Medical Group Co in its US$192 million IPO and listing on the Hong Kong Stock Exchange
- Shanghai Kindly Medical in its US$106 million IPO and listing on the Hong Kong Stock Exchange
- Viva Biotech in its US$194 million IPO and listing on the Hong Kong Stock Exchange
- Gushengtang Holdings (as its US counsel and major shareholders’ counsel) in its US$104 million IPO and listing on the Hong Kong Stock Exchange
- Hygeia Healthcare Holdings (as its US counsel) in its US$286 million IPO and listing on the Hong Kong Stock Exchange
- China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$133 million IPO of mobile game publisher FingerTango Inc on the Hong Kong Stock Exchange
- China Securities (International) Corporate Finance Company Limited, as the sole sponsor and lead underwriter, in the US$40 million IPO of mobile game publisher Digital Hollywood Interactive on the Hong Kong Stock Exchange
- Yeahka (as its US counsel) in its US$212 million IPO and listing on the Hong Kong Stock Exchange
- Honliv Healthcare in its HK$315 million IPO and listing on the Hong Kong Stock Exchange
- Simcere Pharmaceutical (as its US counsel) in its US$416 million IPO and listing on the Hong Kong Stock Exchange
- FIH Mobile Limited’s underwriters, Goldman Sachs and UBS, in its $432 million IPO and listing on the Hong Kong Stock Exchange
- Bank of Tianjin in its US$948 million global offering and IPO on the Hong Kong Stock Exchange
- Bank of China on its $11.2 billion Hong Kong IPO and global offering
- WH Group in its US$2.36 billion global offering and IPO
- Dexin China Holdings in its US$190 million IPO and listing on the Hong Kong Stock Exchange
- CICC, Goldman Sachs, Morgan Stanley, Citigroup, China Merchants Securities and other underwriters in the US$925 million global offering and listing of H shares of Red Star Macalline Group Corporation Ltd
- BOCOM International, ABCI, Qilu International, and other underwriters in the US$454 million global offering and listing of the H-shares of Guolian Securities Co. Ltd
- Haitong International, J.P. Morgan, Credit Suisse, Deutsche Bank, Citigroup and UBS, and other underwriters including HSBC, Nomura, Standard Chartered, and BOCOM International, in the US$1.68 billion H share IPO of Haitong Securities Co. Ltd
- BOCOM International, Morgan Stanley, Standard Chartered, BOCI Asia, CCB International, and other underwriters in the US$87 million global offering and IPO of New Century Real Estate Investment Trust (the first solely China-based hotel REIT listing in the world)
- J.P. Morgan, as the sole sponsor and financial adviser, in China Daye Non-Ferrous Metals Mining Limited’s deemed new listing and reverse takeover resulting from its RMB5.8 billion acquisition of Prosper Well Group Limited
- Citigroup, UBS, and CIMB Securities Limited in the US$214 million global offering and IPO of Fu Shou Yuan International Group Limited
- BOCOM International, Macquarie, BOCI Asia, Haitong International, ICBC International, and ABCI in the US$202 million global offering and IPO of Logan Property Holdings
- Morgan Stanley, CITIC Securities Corporate Finance, ICBC International, and other underwriters in the US$130 million global offering and IPO of China VAST Industrial Urban Development
- CICC and GF Securities in the US$172 million global offering and IPO of H shares of China Aluminum International Engineering Corporation
- Morgan Stanley in the US$180 million global offering of Goodbaby International
- Macquarie, HSBC and Nomura in the US$200 million global offering and IPO of Top Spring International Holdings, which was the first-ever listing to provide a mixed-media offering in Hong Kong
- BOCOM International, Haitong International, KGI Capital, and GF Securities in the US$78 million global offering and spin-off listing of China New City Commercial Development from Zhong An Real Estate
- Goldman Sachs, Morgan Stanley, and HSBC in the spin-off and listing by introduction of Swire Properties
- Merrill Lynch and Morgan Stanley in the HK$2.56 billion spin-off and global offering of Pou Sheng International
- Citigroup, JP Morgan, and Rothschild in the global offering and IPO of Trinity Limited
- ASMC in its HK$700 million H share global offering and IPO sponsored by Goldman Sachs and BOCI
- First Shanghai Capital as sole sponsor and First Shanghai Securities as sole global coordinator, and other underwriters in the US$71 million IPO and listing of Chen Lin Education Group on the Hong Kong Stock Exchange
- UBS and other underwriters in the global offering and IPO of Kasen International
- Guangzhou Automobile’s underwriters on its listing by introduction of Hong Kong Stock Exchange in conjunction with privatization of Denway Motors
- China VAST Industrial Urban Development in its issuance of US$180 million senior notes
- China Communications Construction Group on its $2.4 billion Hong Kong IPO and global offering
- Shanghai Electric on its US$650 million Hong Kong IPO and global offering arranged by Credit Suisse
- China Power’s underwriters in its $369 million Hong Kong IPO
- Want Want China Group on its US$1.05 billion Hong Kong IPO and global offering
- Air China on its $1.2 billion IPO and dual listing on the Hong Kong and London Stock Exchanges
- CITIC Dameng Holding Ltd’s underwriters in its US$266 million IPO
- Morgan Stanley as the sole placing agent in Ping An Insurance Group’s US$4.75 billion private placement of new H-shares (the largest H share placement to date)
- CICC, Deutsche Bank AG, Hong Kong Branch, Guotai Junan Securities and CLSA Limited, as the placing agents, in the HK$4.48 billion private H share placement of Sinopec Oilfield Service Corporation (SSC) on the Hong Kong Stock Exchange
- G-Resources in its placement of new shares raising $100 million
- J.P. Morgan and BNP Paribas as underwriters on Mongolian Mining Corporation’s US$195 million rights issue
- Wai Yuen Tong Medicine in its $30 million rights issue
- Placing agents in the US$1.2 billion top-up placement by Fosun International Limited
- China Everbright’s US$162 million top-up placement
Corporate, Life Science, M&A Transactions and Others
- CLSA and Guotai Junan in the US$145 million secondary placement transaction for new shares issued by XtalPi Holdings Limited
- Home Office Development Limited, as offeror and purchaser in its HK$140 million acquisition of Howkingtech International Holding Limited and in its mandatory general offer for the outstanding shares and options of Howkingtech International
- RemeGen in its exclusive worldwide license agreement with Seagen Inc. (the second largest licensing-out transactions by a Chinese biotech company ever)
- China VAST Industrial Urban Development and its controlling shareholder, Profit East Limited, in the US$285 million all-cash take private proposal by China Jinmao Holdings Group Limited
- Central China Real Estate and its Controlling Shareholder in US$83 Million Share Sale
- State-owned shipping giant China Ocean Shipping (Group) Company, and China COSCO Holdings Company Limited and its associated companies in the landmark restructuring involving both China COSCO Group and China Shipping Group, comprising a series of asset acquisitions and disposals among China COSCO, China Shipping and their respective subsidiaries
- China Unicom in its US$23 billion merger with China Netcom by way of a scheme of arrangement
- China VAST Industrial Urban Development Company Limited and its major shareholder in the sale of approximately US$191 million of shares to China Jinmao Holdings Group Limited, and the issuance of 6% convertible bonds of US$123 million with a 36-month maturity date to China Jinmao
- China VAST Industrial Urban Development and its controlling shareholder Profit East Limited in its sale of approximately 9.99% equity interest to a subsidiary of Shunfeng at US$60.4 million, and the establishment of a joint venture between China VAST and Shenzhen Shunfeng Airport Investment
- BOCOM International (Asia) Limited, as financial advisor to Qingdao Holdings International Limited (499.HK), in the company’s approximately US$305 million extreme very substantial acquisition of an 81.91% stake in Qingdao Rural Construction Finance Leasing
- The buyer consortium in its US$300 million privatization offer for all the H shares of HK listed Shandong Luoxin Pharmaceutical by way of a voluntary conditional cash offer
- Central China Real Estate Limited in its $132 million issuance of new shares to Joy Bright Investments Limited and third party subscribers by way of a whitewash waiver
- Beijing Baoying Chuangfu Investment in its mandatory general offer for the outstanding H shares and domestic shares of Northeast Tiger Pharmaceutical (now known as Baytacare Pharmaceutical)
- Goldman Sachs, Citigroup and China Merchants Securities in connection with the deemed new listing and placing of new shares by Tonic Industries (now known as China Merchants Land Limited)
- Famous Commercial, a subsidiary of Gemdale (Asia) Investment Limited, in its acquisition of a stake in Hong Kong-listed Frasers Property (China) Limited (now known as Gemdale Properties and Investment Corporation Limited) for HK$1.65 billion by way of a mandatory general offer
- OrbusNeich Medical Group in its US$200 million Series A and A-2 Fundraising Rounds
- Metro Victory Holdings in its mandatory general offer for the outstanding shares of Cinderella Media Group Limited (now known as KK Culture Holdings Limited)
- Unitech Enterprises Group in its HK$258 million acquisition of approximately 61.56% of the entire issued share capital of Ford Glory Group (now known as Hua Long Jin Kong Company Limited) by way of a mandatory general offer
- Nat-Ace Pharmaceutical in its approximately US$35 million acquisition of 52.79% of Perception Digital Holdings (now known as HongDa Financial Holding) by way of a mandatory general offer
- Ngai Shun Holdings, a Hong Kong listco, in its acquisition of Anway Real Estate Limited for a total consideration of US$141 million
- Ever Billion Group Limited in its HK$765 million proposed acquisition of CASH Financial Services Group from Celestial Asia Securities Holdings Limited
- China Oriental in its defense of a hostile takeover from Smart Triumph Corporation and its subsequent strategic alliance with ArcelorMittal with a value of US$2.4 billion
- China Unicom in the US$6.3 billion sale of its CDMA business to China Telecom
- Famous Commercial Ltd., a subsidiary of Shanghai-listed Gemdale Corporation, in its US$212 million acquisition of Frasers Property (China) Limited
- Air China on its strategic acquisition of a 29.9 per cent interest in Cathay Pacific
- Shunfeng Photovoltaic, as its US special counsel, in the US$482 million very substantial acquisition of the entire equity interests of Wuxi Suntech Power from its PRC administrator
- Pacific Century CyberWorks, the real estate unit of PCCW Limited, in its proposed US$333 million privatization
- G-Resouces Group in its fund raising in relation to the acquisition of the Martabe gold mining project
- Tencent Holdings in its US$300 million investment in Digital Sky Technologies, one of the first-ever major outbound investment by an Internet company in China
- Fortis Bank in its US$453 million acquisition of Pacific Century Insurance
- Fosun International in various of its acquisitions of and investments into companies listed on the Hong Kong Stock Exchange
- The establishment and formation of share award platforms for numerous Hong Kong listcos
HONORS & AWARDS
- Ranked Individual by Chambers Global for Capital Markets: Equity (International Firms) in China (2022, 2023 and 2024)
- Ranked Individual by Chambers Greater China for Capital Markets: Equity (International Firms) in China (2022, 2023, 2024 and 2025)
- Recognized by Legal 500: Capital Markets (Equity) (2018, 2019, 2020, 2021, 2022 and 2023)
- Ranked Highly Regarded (M&A) by IFLR (2021, 2022 and 2023)
- China Business Law Journal Top 100 Elite Lawyers A List (2022)
- China Business Law Journal A-List 2023-2024: Growth Drivers (2023-2024)
